This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Insulet's Net Loss Widens, But Revenue Improves

Once these most recent quarterly results are finalized, they will be run through TheStreet.com Ratings' model and our ratings will be adjusted accordingly. To keep up to date on all of our ratings, visit TheStreet.com Ratings Screener.

On March 5, 2009, Insulet (PODD - Get Report), a medical device maker, reported that its Q4 FY08 net loss widened, hurt by a restructuring charge and higher expenses. Net loss stood at $28.28 million, or $1.02 per share, compared to a loss of $15.67 million, or $0.59 per share, in Q4 FY07. Net loss was negatively impacted by a restructuring charge of $8.20 million related to the transition of the company's manufacturing activities to China. The most recent consensus estimate was for a loss of $0.64 per share.

Insulet's revenue surged 172.0% to $11.86 million from $4.36 million in the prior year's quarter. The company improved to a gross profit of 10.10% from a gross loss of 53.15% in the prior year's quarter, as revenue outpaced the cost of revenue, which increased 59.6% to $10.66 million from $6.68 million.

During the quarter under review, research and development expenses spiked 11.5% to $3.54 million from $3.17 million. General and administrative costs increased 34.9% to $6.85 million from $5.08 million. Sales and marketing costs surged 82.2% to $10.00 million from $5.49 million in the year-ago quarter. Operating expenses swelled 107.9% to $28.55 million from $13.74 million, due to the expansion of the company's sales organization and infrastructure and a restructuring charge.

PODD recently announced the appointment of Brian Roberts as chief financial officer.

For FY08, net loss widened to $92.79 million, or $3.36 per share, from a loss of $53.54 million, or $3.21 per share, in FY07. Annual revenue soared 169.7% to $36.06 million from $13.37 million a year ago.

Looking forward to 2009, Insulet estimates revenue to be in the range of $55.00 to $65.00 million. The company also expects its operating loss to be in the range of $50.00 to $60.00 million.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
PODD $33.55 8.86%
AAPL $122.37 -0.50%
FB $95.21 -1.84%
GOOG $632.59 0.10%
TSLA $266.79 1.13%

Markets

Chart of I:DJI
DOW 17,745.98 -5.41 -0.03%
S&P 500 2,108.63 +0.06 0.00%
NASDAQ 5,128.7850 +17.0520 0.33%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs